The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Lacutamab in patients with advanced mycosis fungoides: results from the TELLOMAK trial
Pierluigi Porcu, MD, Jefferson Health, Sidney Kimmel Cancer Center, Philadelphia, PA, shares some insights into the safety and efficacy of lacutamab, a novel humanized monoclonal antibody being explored for the treatment of various subtypes of cutaneous T-cell lymphoma (CTCL), including mycosis fungoides (MF) and Sézary syndrome. Dr Porcu shares insights into the mechanism of action of this agent, and then goes on to discuss results from the Phase II TELLOMAK trial (NCT03902184), which is evaluating the efficacy of this agent in several cohorts of patients. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
